Rafael Amado - Dec 29, 2023 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President, Head of Global Oncology Research and Development
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Stock symbol
ZLAB
Transactions as of
Dec 29, 2023
Transactions value $
-$509,169
Form type
4
Date filed
1/3/2024, 07:26 PM
Previous filing
May 2, 2023
Next filing
Mar 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZLAB American Depositary Shares Options Exercise +21K 21K Dec 29, 2023 Direct F1, F2, F3, F4
transaction ZLAB American Depositary Shares Options Exercise +21K +100% 42K Dec 29, 2023 Direct F1, F2, F3
transaction ZLAB American Depositary Shares Sale -$509K -19.4K -46.1% $26.30 22.6K Jan 2, 2024 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Restricted Share Units Options Exercise $0 -21K -100% $0.00* 0 Dec 29, 2023 American Depositary Shares 21K Direct F1, F3, F5
transaction ZLAB Restricted Share Units Options Exercise $0 -21K -20% $0.00 84K Dec 29, 2023 American Depositary Shares 21K Direct F1, F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2 ADSs acquired on vesting of Restricted Share Units. Each ADS represents ten Ordinary Shares of the issuer.
F3 Each Restricted Share Unit represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer.
F4 This number reflects a net reduction of 126,000 ADSs, which represents Restricted Share Units that were previously reported as aggregated with ADSs in Table I and are now separately reported in Table II.
F5 These Restricted Share Units vested in full on 12/30/2023, the first anniversary of the date of grant. Vested shares were delivered to the reporting person following vesting.
F6 These Restricted Share Units vest in equal annual installments over five years beginning on 12/30/2023, the first anniversary of the date of grant. Vested shares will be delivered to the reporting person following vesting.
F7 These ADSs were sold automatically to cover taxes upon vesting of Restricted Share Units.

Remarks:

President, Head of Global Oncology Research and Development